Nuclear functions regulated by the VRK1 kinase

References

• Cullen CF, Brittle AL, Ito T, et al. The conserved kinase NHK-1 is essential for mitotic progression and unifying acentrosomal meiotic spindles in drosophila melanogaster. J Cell Bio. 2005;171(4):593–18. doi: 10.1083/jcb.200508127
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science. 2002;298(5600):1912–1934. doi: 10.1126/science.1075762
   PubMed Web of Science ®Google Scholar
• Nichols RJ, Traktman P. Characterization of three paralogous members of the mammalian vaccinia related kinase family. J Biol Chem. 2004;279(9):7934–7946. doi: 10.1074/jbc.M310813200
   PubMed Web of Science ®Google Scholar
• Campillo-Marcos I, García-González R, Navarro-Carrasco E, et al. The human VRK1 chromatin kinase in cancer biology. Cancer Lett. 2021;503:117–128. doi: 10.1016/j.canlet.2020.12.032
   PubMed Web of Science ®Google Scholar
• Campillo-Marcos I, Lazo PA. Implication of the VRK1 chromatin kinase in the signaling responses to DNA damage: a therapeutic target? Cell Mol Life Sci. 2018;75(13):2375–2388. doi: 10.1007/s00018-018-2811-2
   PubMed Web of Science ®Google Scholar
• Alfert A, Moreno N, Kerl K. The BAF complex in development and disease. Epigenet Chromatin. 2019;12(1):19. doi: 10.1186/s13072-019-0264-y
   PubMedGoogle Scholar
• Kakarougkas A, Ismail A, Chambers AL, et al. Requirement for PBAF in transcriptional repression and repair at DNA breaks in actively transcribed regions of chromatin. Mol Cell. 2014;55(5):723–732. doi: 10.1016/j.molcel.2014.06.028
   PubMed Web of Science ®Google Scholar
• Sanz-Garcia M, Vazquez-Cedeira M, Kellerman E, et al. Substrate profiling of human vaccinia-related kinases identifies coilin, a cajal body nuclear protein, as a phosphorylation target with neurological implications. J Proteomics. 2011;75(2):548–560. doi: 10.1016/j.jprot.2011.08.019
   PubMed Web of Science ®Google Scholar
• Cantarero L, Sanz-Garcia M, Vinograd-Byk H, et al. VRK1 regulates cajal body dynamics and protects coilin from proteasomal degradation in cell cycle. Sci Rep. 2015;5:10543. doi: 10.1038/srep10543
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693–705. doi: 10.1016/j.cell.2007.02.005
   PubMed Web of Science ®Google Scholar
• Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381–395. doi: 10.1038/cr.2011.22
   PubMed Web of Science ®Google Scholar
• Zhao Z, Shilatifard A. Epigenetic modifications of histones in cancer. Genome Biol. 2019;20(1):245. doi: 10.1186/s13059-019-1870-5
   PubMed Web of Science ®Google Scholar
• Nebbioso A, Tambaro FP, Dell’aversana C, et al. Cancer epigenetics: moving forward. PLOS Genet. 2018;14(6):e1007362. doi: 10.1371/journal.pgen.1007362
   PubMed Web of Science ®Google Scholar
• Audia JE, Campbell RM. Histone modifications and cancer. Cold Spring Harb Perspect Biol. 2016;8(4):a019521. doi: 10.1101/cshperspect.a019521
   PubMed Web of Science ®Google Scholar
• MacDonald JL, Tharin S, Hall SE. Epigenetic regulation of nervous system development and function. Neurochem Int. 2022;152:105249. doi: 10.1016/j.neuint.2021.105249
   PubMed Web of Science ®Google Scholar
• Kumar R, Deivendran S, Santhoshkumar TR, et al. Signaling coupled epigenomic regulation of gene expression. Oncogene. 2017;36(43):5917–5926. doi: 10.1038/onc.2017.201
   PubMed Web of Science ®Google Scholar
• Tessarz P, Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nat Rev Mol Cell Biol. 2014;15(11):703–708. doi: 10.1038/nrm3890
   PubMed Web of Science ®Google Scholar
• Valbuena A, Sanz-Garcia M, Lopez-Sanchez I, et al. Roles of VRK1 as a new player in the control of biological processes required for cell division. Cell Signal. 2011;23(8):1267–1272. doi: 10.1016/j.cellsig.2011.04.002
   PubMed Web of Science ®Google Scholar
• Nikalayevich E, Ohkura H. The NuRD nucleosome remodelling complex and NHK-1 kinase are required for chromosome condensation in oocytes. J Cell Sci. 2015;128(3):566–575. doi: 10.1242/jcs.158477
   PubMed Web of Science ®Google Scholar
• Shin J, Chakraborty G, Bharatham N, et al. NMR solution structure of human vaccinia-related kinase 1 (VRK1) reveals the C-terminal tail essential for its structural stability and autocatalytic activity. J Biol Chem. 2011;286(25):22131–22138. doi: 10.1074/jbc.M110.200162
   PubMed Web of Science ®Google Scholar
• Budziszewski GR, Zhao Y, Spangler CJ, et al. Multivalent DNA and nucleosome acidic patch interactions specify VRK1 mitotic localization and activity. Nucleic Acids Res. 2022;50(8):4355–4371. doi: 10.1093/nar/gkac198
   PubMed Web of Science ®Google Scholar
• Aihara H, Nakagawa T, Mizusaki H, et al. Histone H2A T120 phosphorylation promotes oncogenic transformation via upregulation of cyclin D1. Mol Cell. 2016;64(1):176–188. doi: 10.1016/j.molcel.2016.09.012
   PubMed Web of Science ®Google Scholar
• Kang TH, Park DY, Choi YH, et al. Mitotic histone H3 phosphorylation by vaccinia-related kinase 1 in mammalian cells. Mol Cell Biol. 2007;27(24):8533–8546. doi: 10.1128/MCB.00018-07
   PubMed Web of Science ®Google Scholar
• Moura DS, Campillo-Marcos I, Vazquez-Cedeira M, et al. VRK1 and AURKB form a complex that cross inhibit their kinase activity and the phosphorylation of histone H3 in the progression of mitosis. Cell Mol Life Sci. 2018;76(14):2591–2611. doi: 10.1007/s00018-018-2746-7
   Google Scholar
• Garcia-Gonzalez R, Morejon-Garcia P, Campillo-Marcos I, et al. VRK1 phosphorylates Tip60/KAT5 and is required for H4K16 acetylation in response to DNA damage. Cancers (Basel). 2020;12(10):2986. doi: 10.3390/cancers12102986
   PubMed Web of Science ®Google Scholar
• García-González R, Monte-Serrano E, Morejón-García P, et al. The VRK1 chromatin kinase regulates the acetyltransferase activity of Tip60/KAT5 by sequential phosphorylations in response to DNA damage. Biochim Biophys Acta, Gene Regul Mech. 2022;1865(8):194887. doi: 10.1016/j.bbagrm.2022.194887
   PubMed Web of Science ®Google Scholar
• Monte-Serrano E, Lazo PA. VRK1 kinase activity modulating histone H4K16 acetylation inhibited by SIRT2 and VRK-IN-1. Int J Mol Sci. 2023;24(5):4912. doi: 10.3390/ijms24054912
   PubMed Web of Science ®Google Scholar
• Salzano M, Sanz-Garcia M, Monsalve DM, et al. VRK1 chromatin kinase phosphorylates H2AX and is required for foci formation induced by DNA damage. Epigenetics. 2015;10(5):373–383. doi: 10.1080/15592294.2015.1028708
   PubMed Web of Science ®Google Scholar
• Fernandez-Capetillo O, Lee A, Nussenzweig M, et al. H2AX: the histone guardian of the genome. DNA Repair. 2004;3(8–9):959–967. doi: 10.1016/j.dnarep.2004.03.024
   PubMed Web of Science ®Google Scholar
• Maeda K, Yoneda M, Nakagawa T, et al. Defects in centromeric/pericentromeric histone H2A T120 phosphorylation by hBUB1 cause chromosome missegregation producing multinucleated cells. Genes Cells. 2018;23(10):828–838.
   PubMed Web of Science ®Google Scholar
• Lazo PA, Morejón-García P. VRK1 variants at the cross road of cajal body neuropathogenic mechanisms in distal neuropathies and motor neuron diseases. Neurobiol Dis. 2023;183:106172. 10.1016/j.nbd.2023.106172
   PubMed Web of Science ®Google Scholar
• Turner BM. Nucleosome signalling; an evolving concept. Biochim Biophys Acta. 2014;1839(8):623–626. doi: 10.1016/j.bbagrm.2014.01.001
   PubMed Web of Science ®Google Scholar
• Becker PB, Workman JL. Nucleosome remodeling and epigenetics. Cold Spring Harb Perspect Biol. 2013;5(9):a017905. doi: 10.1101/cshperspect.a017905
   PubMed Web of Science ®Google Scholar
• Monte-Serrano E, Morejón-García P, Campillo-Marcos I, et al. The pattern of histone H3 epigenetic posttranslational modifications is regulated by the VRK1 chromatin kinase. Epigenet Chromatin. 2023;16(1):18. doi: 10.1186/s13072-023-00494-7
   PubMed Web of Science ®Google Scholar
• Serafim RAM, de Souza Gama FH, Dutra LA, et al. Development of pyridine-based inhibitors for the human vaccinia-related kinases 1 and 2. ACS Med Chem Lett. 2019;10(9):1266–1271. doi: 10.1021/acsmedchemlett.9b00082
   PubMed Web of Science ®Google Scholar
• Vaquero A, Scher MB, Lee DH, et al. SirT2 is a histone deacetylase with preference for histone H4 lys 16 during mitosis. Genes Dev. 2006;20(10):1256–1261. doi: 10.1101/gad.1412706
   PubMed Web of Science ®Google Scholar
• Vaquero A, Sternglanz R, Reinberg D. Nad±dependent deacetylation of H4 lysine 16 by class III HDACs. Oncogene. 2007;26(37):5505–5520. doi: 10.1038/sj.onc.1210617
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Singh M, Pandita RK, Singh V, Lo CSC, Leonard F, Horikoshi N, Moros EG, Guha D, Hunt CR, et al. Heat-induced SIRT1-mediated H4K16ac deacetylation impairs resection and SMARCAD1 recruitment to double strand breaks. iScience. 2022;25(4):104142. doi: 10.1016/j.isci.2022.104142
   PubMed Web of Science ®Google Scholar
• Navarro-Carrasco E, Lazo PA. VRK1 depletion facilitates the synthetic lethality of temozolomide and olaparib in glioblastoma cells. Front Cell Dev Biol. 2021;9:683038. doi: 10.3389/fcell.2021.683038
   PubMed Web of Science ®Google Scholar
• Campillo-Marcos I, Monte-Serrano E, Navarro-Carrasco E, et al. Lysine methyltransferase inhibitors impair H4K20me2 and 53BP1 foci in response to DNA damage in sarcomas, a synthetic lethality strategy. Front Cell Dev Biol. 2021;9:715126. doi: 10.3389/fcell.2021.715126
   PubMed Web of Science ®Google Scholar
• Santos CR, Rodriguez-Pinilla M, Vega FM, et al. VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma. Mol Cancer Res. 2006;4(3):177–185. doi: 10.1158/1541-7786.MCR-05-0212
   PubMed Web of Science ®Google Scholar
• Valbuena A, López-Sánchez I, Lazo PA, Williams S. Human VRK1 is an early response gene and its loss causes a block in cell cycle progression. PLOS ONE. 2008;3(2):e1642. doi: 10.1371/journal.pone.0001642
   PubMed Web of Science ®Google Scholar
• Lopez-Borges S, Lazo PA. The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. Oncogene. 2000;19(32):3656–3664. doi: 10.1038/sj.onc.1203709
   PubMed Web of Science ®Google Scholar
• Sevilla A, Santos CR, Barcia R, et al. C-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK). Oncogene. 2004;23(55):8950–8958. doi: 10.1038/sj.onc.1208015
   PubMed Web of Science ®Google Scholar
• Sevilla A, Santos CR, Vega FM, et al. Human vaccinia-related kinase 1 (VRK1) activates the ATF2 transcriptional activity by novel phosphorylation on thr-73 and ser-62 and cooperates with JNK. J Biol Chem. 2004;279(26):27458–27465. doi: 10.1074/jbc.M401009200
   PubMed Web of Science ®Google Scholar
• Kang TH, Park DY, Kim W, Kim KT. VRK1 phosphorylates CREB and mediates CCND1 expression. J Cell Sci. 2008;121(Pt 18):3035–3041. doi: 10.1242/jcs.026757
   PubMed Web of Science ®Google Scholar
• Barcia R, Lopez-Borges S, Vega FM, et al. Kinetic properties of p53 phosphorylation by the human vaccinia-related kinase 1. Arch Biochem Biophys. 2002;399(1):1–5. doi: 10.1006/abbi.2001.2746
   PubMed Web of Science ®Google Scholar
• Valbuena A, Suarez-Gauthier A, Lopez-Rios F, et al. Alteration of the VRK1-p53 autoregulatory loop in human lung carcinomas. Lung Cancer. 2007;58(3):303–309. doi: 10.1016/j.lungcan.2007.06.023
   PubMed Web of Science ®Google Scholar
• Vega FM, Gonzalo P, Gaspar ML, et al. Expression of the VRK (vaccinia-related kinase) gene family of p53 regulators in murine hematopoietic development. FEBS Lett. 2003;544(1–3):176–180. doi: 10.1016/S0014-5793(03)00501-5
   PubMed Web of Science ®Google Scholar
• Liu ZC, Cao K, Xiao ZH, et al. VRK1 promotes cisplatin resistance by up-regulating c-MYC via c-Jun activation and serves as a therapeutic target in esophageal squamous cell carcinoma. Oncotarget. 2017;8(39):65642–65658. doi: 10.18632/oncotarget.20020
   PubMedGoogle Scholar
• Colmenero-Repiso A, Gómez-Muñoz MA, Rodríguez-Prieto I, et al. Identification of VRK1 as a new neuroblastoma tumor progression marker regulating cell proliferation. Cancers (Basel). 2020;12(11):3465. doi: 10.3390/cancers12113465
   PubMed Web of Science ®Google Scholar
• Sun X, Zhao W, Wang Q, Zhao J, Yang D, Yang Y. Inhibition of VRK1 suppresses proliferation and migration of vascular smooth muscle cells and intima hyperplasia after injury via mTorc1/β-catenin axis. BMB Rep. 2022;55(5):244–249. doi: 10.5483/BMBRep.2022.55.5.019
   PubMedGoogle Scholar
• Carrión-Marchante R, Frezza V, Salgado-Figueroa A, et al. DNA aptamers against vaccinia-related kinase (VRK) 1 block proliferation in MCF7 breast cancer cells. Pharmaceuticals (Basel). 2021;14(5). 473. doi: 10.3390/ph14050473
   PubMedGoogle Scholar
• Fernandez IF, Blanco S, Lozano J, et al. VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer. Mol Cell Biol. 2010;30(19):4687–4697. doi: 10.1128/MCB.01581-09
   PubMed Web of Science ®Google Scholar
• Fernandez IF, Perez-Rivas LG, Blanco S, Castillo-Dominguez AA, Lozano J, Lazo PA. VRK2 anchors KSR1-MEK1 to endoplasmic reticulum forming a macromolecular complex that compartmentalizes MAPK signaling. Cell Mol Life Sci. 2012;69(22):3881–3893. doi: 10.1007/s00018-012-1056-8
   PubMed Web of Science ®Google Scholar
• Vega FM, Sevilla A, Lazo PA. Lazo PA: p53 stabilization and accumulation induced by human vaccinia-related kinase 1. Mol Cell Biol. 2004;24(23):10366–10380. doi: 10.1128/MCB.24.23.10366-10380.2004
   PubMed Web of Science ®Google Scholar
• Cartwright TN, Harris RJ, Meyer SK, Mon AM, Watson NA, Tan C, Marcelot A, Wang F, Zinn-Justin S, Traktman P, Higgins JMG. Dissecting the roles of haspin and VRK1 in histone H3 phosphorylation during mitosis. Sci Rep. 2022;12(1):11210. doi: 10.1038/s41598-022-15339-8
   PubMed Web of Science ®Google Scholar
• Ryu HG, Jung Y, Lee N, et al. HNRNP A1 promotes lung cancer cell proliferation by modulating VRK1 translation. Int J Mol Sci. 2021;22(11):5506. doi: 10.3390/ijms22115506
   PubMed Web of Science ®Google Scholar
• Choi YH, Lim JK, Jeong MW, et al. HnRNP A1 phosphorylated by VRK1 stimulates telomerase and its binding to telomeric DNA sequence. Nucleic Acids Res. 2012;40(17):8499–8518. doi: 10.1093/nar/gks634
   PubMed Web of Science ®Google Scholar
• Choi YH, Park CH, Kim W, Ling H, Kang A, Chang MW, Im SK, Jeong HW, Kong YY, Kim KT, Milstone DS. Vaccinia-related kinase 1 is required for the maintenance of undifferentiated spermatogonia in mouse male germ cells. PLOS ONE. 2010;5(12):e15254. doi: 10.1371/journal.pone.0015254
   PubMed Web of Science ®Google Scholar
• Wiebe MS, Nichols RJ, Molitor TP, et al. Mice deficient in the serine/threonine protein kinase VRK1 are infertile due to a progressive loss of spermatogonia. Biol Reprod. 2010;82(1):182–193. doi: 10.1095/biolreprod.109.079095
   PubMed Web of Science ®Google Scholar
• Schober CS, Aydiner F, Booth CJ, et al. The kinase VRK1 is required for normal meiotic progression in mammalian oogenesis. Mech Dev. 2011;128(3–4):178–190. doi: 10.1016/j.mod.2011.01.004
   PubMed Web of Science ®Google Scholar
• Kelly AE, Ghenoiu C, Xue JZ, et al. Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase aurora B. Science. 2010;330(6001):235–239. doi: 10.1126/science.1189505
   PubMed Web of Science ®Google Scholar
• Jeong MW, Kang TH, Kim W, et al. Mitogen-activated protein kinase phosphatase 2 regulates histone H3 phosphorylation via interaction with vaccinia-related kinase 1. Mol Biol Cell. 2013;24(3):373–384. doi: 10.1091/mbc.E12-06-0456
   PubMed Web of Science ®Google Scholar
• Yamagishi Y, Honda T, Tanno Y, et al. Two histone marks establish the inner centromere and chromosome bi-orientation. Science. 2010;330(6001):239–243. doi: 10.1126/science.1194498
   PubMed Web of Science ®Google Scholar
• Berenguer I, López-Jiménez P, Mena I, Viera A, Page J, González-Martínez J, Maestre C, Malumbres M, Suja JA, Gómez R. Haspin participates in AURKB recruitment to centromeres and contributes to chromosome congression in male mouse meiosis. J Cell Sci. 2022;135(13). doi: 10.1242/jcs.259546
   PubMed Web of Science ®Google Scholar
• Hirota T, Lipp JJ, Toh BH, et al. Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature. 2005;438(7071):1176–1180. doi: 10.1038/nature04254
   PubMed Web of Science ®Google Scholar
• Ivanovska I, Khandan T, Ito T, et al. A histone code in meiosis: the histone kinase, NHK-1, is required for proper chromosomal architecture in drosophila oocytes. Genes Dev. 2005;19(21):2571–2582. doi: 10.1101/gad.1348905
   PubMed Web of Science ®Google Scholar
• Lancaster OM, Breuer M, Cullen CF, et al. The meiotic recombination checkpoint suppresses NHK-1 kinase to prevent reorganisation of the oocyte nucleus in Drosophila. PLOS Genet. 2010;6(10):e1001179. doi: 10.1371/journal.pgen.1001179
   PubMed Web of Science ®Google Scholar
• Kim J, Choi YH, Chang S, et al. Defective folliculogenesis in female mice lacking vaccinia-related kinase 1. Sci Rep. 2012;2(1):468. doi: 10.1038/srep00468
   PubMedGoogle Scholar
• Lancaster OM, Cullen CF, Ohkura H. NHK-1 phosphorylates BAF to allow karyosome formation in the drosophila oocyte nucleus. J Cell Bio. 2007;179(5):817–824. doi: 10.1083/jcb.200706067
   PubMed Web of Science ®Google Scholar
• Feinstein TN, Linstedt AD, Glick B. Mitogen-activated protein kinase kinase 1-dependent golgi unlinking occurs in G2 phase and promotes the G2/M cell cycle transition. Mol Biol Cell. 2007;18(2):594–604. doi: 10.1091/mbc.E06-06-0530
   PubMed Web of Science ®Google Scholar
• Shaul YD, Seger R. ERK1c regulates golgi fragmentation during mitosis. J Cell Bio. 2006;172(6):885–897. doi: 10.1083/jcb.200509063
   PubMed Web of Science ®Google Scholar
• Ruan Q, Wang Q, Xie S, et al. Polo-like kinase 3 is Golgi localized and involved in regulating Golgi fragmentation during the cell cycle. Exp Cell Res. 2004;294(1):51–59. doi: 10.1016/j.yexcr.2003.10.022
   PubMed Web of Science ®Google Scholar
• Lopez-Sanchez I, Sanz-Garcia M, Lazo PA. Plk3 interacts with and specifically phosphorylates VRK1 in Ser342, a downstream target in a pathway that induces golgi fragmentation. Mol Cell Biol. 2009;29(5):1189–1201. doi: 10.1128/MCB.01341-08
   PubMed Web of Science ®Google Scholar
• Blanco S, Klimcakova L, Vega FM, et al. The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines. FEBS J. 2006;273(11):2487–2504. doi: 10.1111/j.1742-4658.2006.05256.x
   PubMed Web of Science ®Google Scholar
• Sanz-Garcia M, Lopez-Sanchez I, Lazo PA. Proteomics identification of nuclear ran GTPase as an inhibitor of human VRK1 and VRK2 (vaccinia-related kinase) activities. Mol & Cell Proteomics. 2008;7(11):2199–2214. doi: 10.1074/mcp.M700586-MCP200
   PubMed Web of Science ®Google Scholar
• Adam S, Dabin J, Polo SE. Chromatin plasticity in response to DNA damage: the shape of things to come. DNA Repair. 2015;32:120–126. doi: 10.1016/j.dnarep.2015.04.022
   PubMed Web of Science ®Google Scholar
• Santos Á D, Cook AW, Gough RE, Schilling M, Olszok NA, Brown I, Wang L, Aaron J, Martin-Fernandez ML, Rehfeldt F, Toseland CP. DNA damage alters nuclear mechanics through chromatin reorganization. Nucleic Acids Res. 2021;49(1):340–353. doi: 10.1093/nar/gkaa1202
   PubMed Web of Science ®Google Scholar
• Navarro-Carrasco E, Campos-Díaz A, Monte-Serrano E, Rolfs F, de Goeij-de Haas R, Pham TV, Piersma SR, Jiménez CR, Lazo PA. Loss of VRK1 alters the nuclear phosphoproteome in the DNA damage response to doxorubicin. Chem Biol Interact. 2024;2024:110908. doi: 10.1016/j.cbi.2024.110908
   Google Scholar
• Navarro-Carrasco E, Monte-Serrano E, Campos-Díaz A, et al. VRK1 regulates sensitivity to oxidative stress by altering histone epigenetic modifications and the nuclear phosphoproteome in tumor cells. Int J Mol Sci. 2024;25(9):4874. doi: 10.3390/ijms25094874
   PubMedGoogle Scholar
• Sanz-Garcia M, Monsalve DM, Sevilla A, et al. Vaccinia-related kinase 1 (VRK1) is an upstream nucleosomal kinase required for the assembly of 53BP1 foci in response to ionizing radiation-induced DNA damage. J Biol Chem. 2012;287(28):23757–23768. doi: 10.1074/jbc.M112.353102
   PubMed Web of Science ®Google Scholar
• Barcia-Sanjurjo I, Vazquez-Cedeira M, Barcia R, et al. Sensitivity of the kinase activity of human vaccinia-related kinase proteins to toxic metals. J Biol Inorg Chem. 2013;18(4):473–482. doi: 10.1007/s00775-013-0992-6
   PubMed Web of Science ®Google Scholar
• Salzano M, Vazquez-Cedeira M, Sanz-Garcia M, Valbuena A, Blanco S, Fernandez IF, Lazo PA. Vaccinia-related kinase 1 (VRK1) confers resistance to DNA-damaging agents in human breast cancer by affecting DNA damage response. Oncotarget. 2014;5(N7):1770–1778. doi: 10.18632/oncotarget.1678
   PubMedGoogle Scholar
• Monsalve DM, Campillo-Marcos I, Salzano M, Sanz-Garcia M, Cantarero L, Lazo PA. VRK1 phosphorylates and protects NBS1 from ubiquitination and proteasomal degradation in response to DNA damage. Biochim Biophys Acta Mol Cell Res. 2016;1863(4):760–769. doi: 10.1016/j.bbamcr.2016.02.005
   Web of Science ®Google Scholar
• Martin-Doncel E, Rojas AM, Cantarero L, Lazo PA. VRK1 functional insufficiency due to alterations in protein stability or kinase activity of human VRK1 pathogenic variants implicated in neuromotor syndromes. Sci Rep. 2019;9(1):13381. doi: 10.1038/s41598-019-49821-7
   PubMedGoogle Scholar
• Navarro-Carrasco E, Campos-Díaz A, Monte-Serrano E, Rolfs F, de Goeij-de Haas R, Pham TV, Piersma SR, Jiménez CR, Lazo PA. Loss of VRK1 alters the nuclear phosphoproteome in the DNA damage response to doxorubicin. Chem Biol Interact. 2024;391:110908. doi: 10.1016/j.cbi.2024.110908
   PubMed Web of Science ®Google Scholar
• Campillo-Marcos I, Lazo PA. Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase. J Exp Clin Cancer Res. 2019;38(1):203. doi: 10.1186/s13046-019-1204-1
   PubMedGoogle Scholar
• Maynard S, Fang EF, Scheibye-Knudsen M, et al. DNA damage, DNA repair, aging, and neurodegeneration. Cold Spring Harb Perspect Med. 2015;5(10):a025130. doi: 10.1101/cshperspect.a025130
   PubMed Web of Science ®Google Scholar
• Sun Y, Curle AJ, Haider AM, Balmus G. The role of DNA damage response in amyotrophic lateral sclerosis. Essays Biochem. 2020;64(5):847–861. doi: 10.1042/ebc20200002
   PubMed Web of Science ®Google Scholar
• Madabhushi R, Pan L, Tsai LH. DNA damage and its links to neurodegeneration. Neuron. 2014;83(2):266–282. doi: 10.1016/j.neuron.2014.06.034
   PubMed Web of Science ®Google Scholar
• Lafarga M, Tapia O, Romero AM, et al. Cajal bodies in neurons. RNA Biol. 2017;14(6):712–725. doi: 10.1080/15476286.2016.1231360
   PubMed Web of Science ®Google Scholar
• Tapia O, Narcís JO, Riancho J, et al. Cellular bases of the RNA metabolism dysfunction in motor neurons of a murine model of spinal muscular atrophy: role of cajal bodies and the nucleolus. Neurobiol Dis. 2017;108:83–99. doi: 10.1016/j.nbd.2017.08.004
   PubMed Web of Science ®Google Scholar
• Singh RN, Howell MD, Ottesen EW, et al. Diverse role of survival motor neuron protein. Biochim Biophys Acta Gene Regul Mech. Biochim Biophys Acta Gene Regul Mech. 2017;1860(3):299–315. doi: 10.1016/j.bbagrm.2016.12.008
   PubMed Web of Science ®Google Scholar
• Biton S, Barzilai A, Shiloh Y. The neurological phenotype of ataxia-telangiectasia: solving a persistent puzzle. DNA Repair. 2008;7(7):1028–1038. doi: 10.1016/j.dnarep.2008.03.006
   PubMed Web of Science ®Google Scholar
• Lavin MF. ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene. 2007;26(56):7749–7758. doi: 10.1038/sj.onc.1210880
   PubMed Web of Science ®Google Scholar
• Houldsworth A. Role of oxidative stress in neurodegenerative disorders: a review of reactive oxygen species and prevention by antioxidants. Brain Com. 2024;6(1):fcad356. doi: 10.1093/braincomms/fcad356
   PubMedGoogle Scholar
• Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006;6(12):909–923. doi: 10.1038/nrc2012
   PubMed Web of Science ®Google Scholar
• Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer. 2009;9(10):714–723. doi: 10.1038/nrc2716
   PubMed Web of Science ®Google Scholar
• Lazo PA. Reverting p53 activation after recovery of cellular stress to resume with cell cycle progression. Cell Signal. 2017;33:49–58. doi: 10.1016/j.cellsig.2017.02.005
   PubMed Web of Science ®Google Scholar
• Lopez-Sanchez I, Valbuena A, Vazquez-Cedeira M, et al. VRK1 interacts with p53 forming a basal complex that is activated by UV-induced DNA damage. FEBS Lett. 2014;588(5):692–700. doi: 10.1016/j.febslet.2014.01.040
   PubMed Web of Science ®Google Scholar
• Valbuena A, Vega FM, Blanco S. Lazo PA: p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop. Mol Cell Biol. 2006;26(13):4782–4793. doi: 10.1128/MCB.00069-06
   PubMed Web of Science ®Google Scholar
• Schon O, Friedler A, Bycroft M, et al. Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol. 2002;323(3):491–501. doi: 10.1016/S0022-2836(02)00852-5
   PubMed Web of Science ®Google Scholar
• Teufel DP, Bycroft M, Fersht AR. Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2. Oncogene. 2009;28(20):2112–2118. doi: 10.1038/onc.2009.71
   PubMed Web of Science ®Google Scholar
• Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 2003;10(4):431–442. doi: 10.1038/sj.cdd.4401183
   PubMed Web of Science ®Google Scholar
• Valbuena A, Castro-Obregon S, Lazo PA, Wu GS. Downregulation of VRK1 by p53 in response to DNA Damage is Mediated by the autophagic pathway. PLOS ONE. 2011;6(2):e17320. doi: 10.1371/journal.pone.0017320
   PubMed Web of Science ®Google Scholar
• Valbuena A, Blanco S, Vega FM, Lazo PA, Fugmann SD. The C/H3 domain of p300 is required to protect VRK1 and VRK2 from their downregulation induced by p53. PLOS ONE. 2008;3(7):e2649. doi: 10.1371/journal.pone.0002649
   PubMed Web of Science ®Google Scholar
• Gorjanacz M, Klerkx EP, Galy V, et al. Caenorhabditis elegans BAF-1 and its kinase VRK-1 participate directly in post-mitotic nuclear envelope assembly. Embo J. 2008;26(1):132–143. doi: 10.1038/sj.emboj.7601470
   Web of Science ®Google Scholar
• Burger M, Schmitt-Koopmann C, Leroux JC. DNA unchained: two assays to discover and study inhibitors of the DNA clustering function of barrier-to-autointegration factor. Sci Rep. 2020;10(1):12301. doi: 10.1038/s41598-020-69246-x
   PubMed Web of Science ®Google Scholar
• Zheng R, Ghirlando R, Lee MS, et al. Barrier-to-autointegration factor (BAF) bridges DNA in a discrete, higher-order nucleoprotein complex. Proc Natl Acad Sci USA. 2000;97(16):8997–9002. doi: 10.1073/pnas.150240197
   PubMed Web of Science ®Google Scholar
• Margalit A, Segura-Totten M, Gruenbaum Y, et al. Barrier-to-autointegration factor is required to segregate and enclose chromosomes within the nuclear envelope and assemble the nuclear lamina. Proc Natl Acad Sci USA. 2005;102(9):3290–3295. doi: 10.1073/pnas.0408364102
   PubMed Web of Science ®Google Scholar
• Montes de Oca R, Shoemaker CJ, Gucek M, et al. Barrier-to-autointegration factor proteome reveals chromatin-regulatory partners. PLOS ONE. 2009;4(9):e7050. doi: 10.1371/journal.pone.0007050
   PubMed Web of Science ®Google Scholar
• Nichols RJ, Wiebe MS, Traktman P. The vaccinia-related kinases phosphorylate the N’ terminus of BAF, regulating its interaction with DNA and its retention in the nucleus. Mol Biol Cell. 2006;17(5):2451–2464. doi: 10.1091/mbc.E05-12-1179
   PubMed Web of Science ®Google Scholar
• Molitor TP, Traktman P, Hetzer M. Depletion of the protein kinase VRK1 disrupts nuclear envelope morphology and leads to BAF retention on mitotic chromosomes. Mol Biol Cell. 2014;25(6):891–903. doi: 10.1091/mbc.E13-10-0603
   PubMed Web of Science ®Google Scholar
• Torras-Llort M, Medina-Giró S, Escudero-Ferruz P, et al. A fraction of barrier-to-autointegration factor (BAF) associates with centromeres and controls mitosis progression. Commun Biol. 2020;3(1):454. doi: 10.1038/s42003-020-01182-y
   PubMed Web of Science ®Google Scholar
• Jamin A, Wiebe MS. Barrier to autointegration factor (BANF1): interwoven roles in nuclear structure, genome integrity, innate immunity, stress responses and progeria. Curr Opin Cell Biol. 2015;34:61–68. doi: 10.1016/j.ceb.2015.05.006
   PubMed Web of Science ®Google Scholar
• Bengtsson L, Wilson KL. Barrier-to-autointegration factor phosphorylation on ser-4 regulates emerin binding to lamin a in vitro and emerin localization in vivo. Mol Biol Cell. 2006;17(3):1154–1163. doi: 10.1091/mbc.e05-04-0356
   PubMed Web of Science ®Google Scholar
• Skoko D, Li M, Huang Y, et al. Barrier-to-autointegration factor (BAF) condenses DNA by looping. Proc Natl Acad Sci USA. 2009;106(39):16610–16615. doi: 10.1073/pnas.0909077106
   PubMed Web of Science ®Google Scholar
• Zhuang X, Semenova E, Maric D, et al. Dephosphorylation of barrier-to-autointegration factor by protein phosphatase 4 and its role in cell mitosis. J Biol Chem. 2014;289(2):1119–1127. doi: 10.1074/jbc.M113.492777
   PubMed Web of Science ®Google Scholar
• Marcelot A, Petitalot A, Ropars V, et al. Di-phosphorylated BAF shows altered structural dynamics and binding to DNA, but interacts with its nuclear envelope partners. Nucleic Acids Res. 2021;49(7):3841–3855. doi: 10.1093/nar/gkab184
   PubMed Web of Science ®Google Scholar
• Ren Z, Geng J, Xiong C, et al. Downregulation of VRK1 reduces the expression of BANF1 and suppresses the proliferative and migratory activity of esophageal cancer cells. Oncol Lett. 2020;20(2):1163–1170. doi: 10.3892/ol.2020.11654
   PubMed Web of Science ®Google Scholar
• Asencio C, Davidson IF, Santarella-Mellwig R, et al. Coordination of kinase and phosphatase activities by Lem4 enables nuclear envelope reassembly during mitosis. Cell. 2012;150(1):122–135. doi: 10.1016/j.cell.2012.04.043
   PubMed Web of Science ®Google Scholar
• Gorjanacz M. LEM-4 promotes rapid dephosphorylation of BAF during mitotic exit. Nucleus. 2012;4(1):14–17. doi: 10.4161/nucl.22961
   PubMed Web of Science ®Google Scholar
• Kaufmann T, Kukolj E, Brachner A, et al. SIRT2 regulates nuclear envelope reassembly through ANKLE2 deacetylation. J Cell Sci. 2016;129(24):4607–4621. doi: 10.1242/jcs.192633
   PubMed Web of Science ®Google Scholar
• Apridita Sebastian W, Shiraishi H, Shimizu N, et al. Ankle2 deficiency-associated microcephaly and spermatogenesis defects in zebrafish are alleviated by heterozygous deletion of vrk1. Biochem Biophys Res Commun. 2022;624:95–101. doi: 10.1016/j.bbrc.2022.07.070
   PubMed Web of Science ®Google Scholar
• Carrasco Apolinario ME, Umeda R, Teranishi H, Shan M, Phurpa SW, Lai S, Shimizu N, Shiraishi H, Shikano K, et al. Behavioral and neurological effects of Vrk1 deficiency in zebrafish. Biochem Biophys Res Commun. 2023;675:10–18. doi: 10.1016/j.bbrc.2023.07.005
   PubMed Web of Science ®Google Scholar
• Gonzaga-Jauregui C, Lotze T, Jamal L, et al. Mutations in VRK1 associated with complex motor and sensory axonal neuropathy plus microcephaly. JAMA Neurol. 2013;70(12):1491–1498. doi: 10.1001/jamaneurol.2013.4598
   PubMed Web of Science ®Google Scholar
• Bradley CM, Ronning DR, Ghirlando R, et al. Structural basis for DNA bridging by barrier-to-autointegration factor. Nat Struct Mol Biol. 2005;12(10):935–936. doi: 10.1038/nsmb989
   PubMed Web of Science ®Google Scholar
• Burgess JT, Cheong CM, Suraweera A, et al. Barrier-to-autointegration-factor (Banf1) modulates DNA double-strand break repair pathway choice via regulation of DNA-dependent kinase (DNA-PK) activity. Nucleic Acids Res. 2021;49(6):3294–3307. doi: 10.1093/nar/gkab110
   PubMed Web of Science ®Google Scholar
• Bolderson E, Burgess JT, Li J, Gandhi NS, Boucher D, Croft LV, Beard S, Plowman JJ, Suraweera A, Adams MN, et al. Barrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damage. Nat Commun. 2019;10(1):5501. doi: 10.1038/s41467-019-13167-5
   PubMed Web of Science ®Google Scholar
• Prissette M, Fury W, Koss M, et al. Disruption of nuclear envelope integrity as a possible initiating event in tauopathies. Cell Rep. 2022;40(8):111249. doi: 10.1016/j.celrep.2022.111249
   PubMed Web of Science ®Google Scholar
• Ramon y Cajal S. Un sencillo metodo de coloracion selectiva del reticulo protoplasmatico y sus efectos en los diversos organos nerviosos de vertebrados e invertebrados. Trab Lab Invest Biol (Madrid). 1903;2:129–221.
   Google Scholar
• Hebert MD, Matera AG, Silver PA. Self-association of coilin reveals a common theme in nuclear body localization. Mol Biol Cell. 2000;11(12):4159–4171. doi: 10.1091/mbc.11.12.4159
   PubMed Web of Science ®Google Scholar
• Hebert MD, Poole AR. Towards an understanding of regulating cajal body activity by protein modification. RNA Biol. 2017;14(6):761–778. doi: 10.1080/15476286.2016.1243649
   PubMed Web of Science ®Google Scholar
• Staněk D. Coilin and Cajal bodies. Nucleus. 2023;14(1):2256036. doi: 10.1080/19491034.2023.2256036
   PubMed Web of Science ®Google Scholar
• Machyna M, Heyn P, Neugebauer KM. Cajal bodies: where form meets function. Wiley Interdiscip Rev RNA. 2013;4(1):17–34. doi: 10.1002/wrna.1139
   PubMed Web of Science ®Google Scholar
• Hearst SM, Gilder AS, Negi SS, Davis MD, George EM, Whittom AA, Toyota CG, Husedzinovic A, Gruss OJ, Hebert MD. Cajal-body formation correlates with differential coilin phosphorylation in primary and transformed cell lines. J Cell Sci. 2009;122(Pt 11):1872–1881 doi: 10.1242/jcs.044040
   PubMed Web of Science ®Google Scholar
• Geisler MS, Kemp JP Jr., Duronio RJ. Duronio RJ: histone locus bodies: a paradigm for how nuclear biomolecular condensates control cell cycle regulated gene expression. Nucleus. 2023;14(1):2293604. doi: 10.1080/19491034.2023.2293604
   PubMed Web of Science ®Google Scholar
• Suzuki H, Abe R, Shimada M, et al. The 3’ pol II pausing at replication-dependent histone genes is regulated by mediator through cajal bodies’ association with histone locus bodies. Nat Commun. 2022;13(1):2905. doi: 10.1038/s41467-022-30632-w
   PubMed Web of Science ®Google Scholar
• Arias Escayola D, Neugebauer KM. Dynamics and function of nuclear bodies during embryogenesis. Biochemistry. 2018;57(17):2462–2469. doi: 10.1021/acs.biochem.7b01262
   PubMed Web of Science ®Google Scholar
• Nizami Z, Deryusheva S, Gall JG. The cajal body and histone locus body. Cold Spring Harbor Perspect Biol. 2010;2(7):a000653. doi: 10.1101/cshperspect.a000653
   PubMed Web of Science ®Google Scholar
• Machyna M, Kehr S, Straube K, et al. The coilin interactome identifies hundreds of small noncoding RNAs that traffic through cajal bodies. Mol Cell. 2014;56(3):389–399. doi: 10.1016/j.molcel.2014.10.004
   PubMed Web of Science ®Google Scholar
• Morejon-Garcia P, Keren B, Marcos-Alcalde I, et al. Dysfunctional homozygous VRK1-D263G variant impairs the Assembly of Cajal Bodies and DNA damage response in hereditary spastic paraplegia. Neurol Genet. 2021;7(5):e624. doi: 10.1212/nxg.0000000000000624
   PubMed Web of Science ®Google Scholar
• Marcos AT, Martin-Doncel E, Morejon-Garcia P, et al. VRK1 (Y213H) homozygous mutant impairs cajal bodies in a hereditary case of distal motor neuropathy. Ann Clin Transl Neurol. 2020;7(5):808–818. doi: 10.1002/acn3.51050
   PubMed Web of Science ®Google Scholar
• Bos R, Rihan K, Quintana P, El-Bazzal L, Bernard-Marissal N, Da Silva N, Jabbour R, Mégarbané A, Bartoli M, Brocard F, Delague V. Altered action potential waveform and shorter axonal initial segment in hiPSC-derived motor neurons with mutations in VRK1. Neurobiology of Disease. 2022;2022:105609. doi: 10.1016/j.nbd.2021.105609
   Google Scholar
• Lee YJ, Rio DC. A mutation in the low-complexity domain of splicing factor hnRNPA1 linked to amyotrophic lateral sclerosis disrupts distinct neuronal RNA splicing networks. Genes Dev. 2024;38(1–2):11–30. doi: 10.1101/gad.351104.123
   PubMedGoogle Scholar
• Beijer D, Kim HJ, Guo L, et al. Characterization of HNRNPA1 mutations defines diversity in pathogenic mechanisms and clinical presentation. JCI Insight. 2021;6(14). doi: 10.1172/jci.insight.148363
   PubMed Web of Science ®Google Scholar
• Molitor TP, Traktman P. Molecular genetic analysis of VRK1 in mammary epithelial cells: depletion slows proliferation in vitro and tumor growth and metastasis in vivo. Oncogenesis. 2013;2(6):e48. doi: 10.1038/oncsis.2013.11
   PubMed Web of Science ®Google Scholar
• Mon AM, MacKinnon AC Jr., Traktman P. Traktman P: overexpression of the VRK1 kinase, which is associated with breast cancer, induces a mesenchymal to epithelial transition in mammary epithelial cells. PLOS ONE. 2018;13(9):e0203397. doi: 10.1371/journal.pone.0203397
   PubMed Web of Science ®Google Scholar
• Liu J, Wang Y, He S, et al. Expression of vaccinia-related kinase 1 (VRK1) accelerates cell proliferation but overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma. Hematology. 2016;21(10):603–612. doi: 10.1080/10245332.2016.1147678
   PubMed Web of Science ®Google Scholar
• Du N, Zhang B, Zhang Y. Downregulation of VRK1 inhibits progression of lung squamous cell carcinoma through DNA damage. Can Respir J. 2023;2023:4533504. doi: 10.1155/2023/4533504
   PubMed Web of Science ®Google Scholar
• Li J, Wang T, Pei L, et al. Expression of VRK1 and the downstream gene BANF1 in esophageal cancer. Biomed Pharmacother. 2017;89:1086–1091. doi: 10.1016/j.biopha.2017.02.095
   PubMed Web of Science ®Google Scholar
• Wang L, Zhai R, Shen H, et al. VRK1 promotes proliferation, migration, and invasion of gastric carcinoma cells by activating β-catenin. Neoplasma. 2021;68(5):1005–1014. doi: 10.4149/neo_2021_210304N278
   PubMed Web of Science ®Google Scholar
• Chen D, Zhou W, Chen J, Wang J. Comprehensively prognostic and immunological analysis of VRK Serine/Threonine kinase 1 in pan-cancer and identification in hepatocellular carcinoma. Aging (Albany NY). 2023;15(24):15504–15524. doi: 10.18632/aging.205389
   PubMedGoogle Scholar
• Hennig EE, Mikula M, Rubel T, Dadlez M, Ostrowski J. Comparative kinome analysis to identify putative colon tumor biomarkers. J Mol Med (Berl). 2012;90(4):447–456. doi: 10.1007/s00109-011-0831-6
   PubMed Web of Science ®Google Scholar
• Martin KJ, Patrick DR, Bissell MJ, Fournier MV, Preiss T. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLOS ONE. 2008;3(8):e2994. doi: 10.1371/journal.pone.0002994
   PubMed Web of Science ®Google Scholar
• Zhao X, Chu X, Song L, et al. A novel model incorporating chromatin regulatory factors for risk stratification, prognosis prediction, and characterization of the microenvironment in Wilms tumor. The Journal of Gene Medicine. 2024;2023(1):e3574. doi: 10.1002/jgm.3574
   Google Scholar
• Ben Z, Gong L, Qiu Y. High expression of VRK1 is related to poor prognosis in glioma. Pathol Res Pract. 2018;214(1):112–118. doi: 10.1016/j.prp.2017.10.014
   PubMed Web of Science ®Google Scholar
• So J, Mabe NW, Englinger B, Chow KH, Moyer SM, Yerrum S, Trissal MC, Marques JG, Kwon JJ, Shim B, et al. VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system. JCI Insight. 2022;7(19). doi: 10.1172/jci.insight.158755
   PubMed Web of Science ®Google Scholar
• Varghese RT, Liang Y, Guan T, et al. Survival kinase genes present prognostic significance in glioblastoma. Oncotarget. 2016;7(15):20140–20151. doi: 10.18632/oncotarget.7917
   PubMedGoogle Scholar
• Eswaran J, Patnaik D, Filippakopoulos P, Wang F, Stein RL, Murray JW, Higgins JM, Knapp S. Structure and functional characterization of the atypical human kinase haspin. Proc Natl Acad Sci USA. 2009;106(48):20198–20203. doi: 10.1073/pnas.0901989106
   PubMed Web of Science ®Google Scholar
• Fedorov O, Marsden B, Pogacic V, et al. A systematic interaction map of validated kinase inhibitors with ser/thr kinases. Proc Natl Acad Sci USA. 2007;104(51):20523–20528. doi: 10.1073/pnas.0708800104
   PubMed Web of Science ®Google Scholar
• Fedorov O, Sundstrom M, Marsden B, et al. Insights for the development of specific kinase inhibitors by targeted structural genomics. Drug Discov Today. 2007;12(9–10):365–372. doi: 10.1016/j.drudis.2007.03.006
   PubMed Web of Science ®Google Scholar
• Vazquez-Cedeira M, Barcia-Sanjurjo I, Sanz-Garcia M, et al. Differential inhibitor sensitivity between human kinases VRK1 and VRK2. PLOS ONE. 2011;6(8):e23235. doi: 10.1371/journal.pone.0023235
   PubMed Web of Science ®Google Scholar
• Ngow YS, Rajan S, Ye H, Yoon HS. Crystal structure of human Vaccinia-related kinase 1 (VRK1) in complex with AMP-PNP, a non-hydrolysable ATP analog. Protein Science. 2019;28(3):524–532. doi: 10.1002/pro.3552
   PubMed Web of Science ®Google Scholar
• Couñago RM, Allerston CK, Savitsky P, et al. Structural characterization of human vaccinia-related kinases (VRK) bound to small-molecule inhibitors identifies different P-loop conformations. Sci Rep. 2017;7(1):7501. doi: 10.1038/s41598-017-07755-y
   PubMedGoogle Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12–27. doi: 10.1016/j.cell.2012.06.013
   PubMed Web of Science ®Google Scholar
• Simó-Riudalbas L, Esteller M. Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br J Pharmacol. 2015;172(11):2716–2732. doi: 10.1111/bph.12844
   PubMed Web of Science ®Google Scholar
• Fradet-Turcotte A, Canny MD, Escribano-Díaz C, Orthwein A, Leung CC, Huang H, Landry MC, Kitevski-LeBlanc J, Noordermeer SM, Sicheri F, Durocher D. 53BP1 is a reader of the DNA-damage-induced H2A lys 15 ubiquitin mark. Nature. 2013;499(7456):50–54. doi: 10.1038/nature12318
   PubMed Web of Science ®Google Scholar
• Tang J, Cho NW, Cui G, et al. Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination. Nat Struct Mol Biol. 2013;20(3):317–325. doi: 10.1038/nsmb.2499
   PubMed Web of Science ®Google Scholar
• He X, Zai G, Zhou L, et al. Identification of VRK1 as a novel potential biomarker for prognosis and immunotherapy in hepatocellular carcinoma. J Inflamm Res. 2024;17:1671–1683. doi: 10.2147/JIR.S452505
   PubMed Web of Science ®Google Scholar
• Fan Z, Wang X, Cheng H, Pan M. VRK1 promotes DNA-induced type I interferon production. Mol Biol Rep. 2024;51(1):453. doi: 10.1007/s11033-024-09414-8
   PubMed Web of Science ®Google Scholar
• Shields JA, Meier SR, Bandi M, Mulkearns-Hubert EE, Hajdari N, Dam Ferdinez M, Engel JL, Silver DJ, Shen B, Zhang W, et al. VRK1 is a synthetic–lethal target in VRK2-deficient glioblastoma. Cancer Research. 2022. 82(21):4044–4057. doi: 10.1158/0008-5472.Can-21-4443
   PubMed Web of Science ®Google Scholar